Sugimura Y, Sakurai M, Hioki T, Hayashi N, Yamakawa K, Tajima K, Tochigi H, Kawamura J
Department of Urology, Mie University School of Medicine.
Hinyokika Kiyo. 1988 Dec;34(12):2129-34.
The serum levels of gamma-Seminoprotein (gamma-Sm) were determined by enzyme immunoassay in 77 patients with prostatic cancer (30 untreated and 47 treated), 44 patients with benign prostatic hypertrophy and 12 patients with prostatitis. Serum levels of gamma-Sm in each disease were as follows; untreated prostatic cancer 23.2 +/- 18.3 ng/ml (positive rate 93%), treated prostatic cancer 4.7 +/- 8.3 (positive rate 25.5%), benign prostatic hypertrophy 3.6 +/- 3.3 (positive rate 23.7%), prostatitis 2.0 +/- 2.0 (positive rate 7.7%). Serum gamma-Sm levels in prostatic cancer were higher in advanced stage but relatively low in poorly differentiated adenocarcinoma. We consider that the level of serum gamma-Sm is a useful tumor marker as well as prostatic acid phosphatase (PAP) in diagnosis and follow-up of the patients with prostatic cancer.
采用酶免疫分析法测定了77例前列腺癌患者（30例未经治疗，47例接受过治疗）、44例良性前列腺增生患者和12例前列腺炎患者的血清γ-精浆蛋白（γ-Sm）水平。每种疾病的血清γ-Sm水平如下：未经治疗的前列腺癌为23.2±18.3 ng/ml（阳性率93%），接受过治疗的前列腺癌为4.7±8.3（阳性率25.5%），良性前列腺增生为3.6±3.3（阳性率23.7%），前列腺炎为2.0±2.0（阳性率7.7%）。前列腺癌患者血清γ-Sm水平在晚期较高，但在低分化腺癌中相对较低。我们认为血清γ-Sm水平在前列腺癌患者的诊断和随访中是一种有用的肿瘤标志物，与前列腺酸性磷酸酶（PAP）一样。
